News Formal

New Ozempic Rival Is About to Make Your Weight Loss Drugs Cheaper

  • 📰 BNNBloomberg
  • ⏱ Reading Time:
  • 26 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 50%

Business Business Headlines News

Business Business Latest News,Business Business Headlines

An effective and massively popular weight-loss drug has made Novo Nordisk A/S billions of dollars and turned it into the most valuable company in Europe. With the US Food and Drug Administration approval of another option from Eli Lilly & Co. on Wednesday, the Danish drugmaker now has some serious competition.

Asian Stocks to Climb as S&P 500 Hits Hot Streak: Markets WrapBill Holdings Nears $1.

Slides After Wider-Than-Expected Quarterly LossAsian Stocks to Climb as S&P 500 Hits Hot Streak: Markets WrapIsrael Latest: Saudi Arabia Says Normalization Talks to ContinueZinc Gains With Focus on Supply Amid Drawdown of LME StockpilesPanama Canal Queue Jumper Pays Record $4 Million to Skip LineEurope to Extend Emergency Energy Measures on Middle East RisksBond Sales Are Becoming a Bigger Deal for Stocks Than US Jobs DataEgypt’s Dollar Shortages Hit Profits for a Top US Grain HandlerBank...

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 83. in BUSİNESS

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Eli Lilly Wins FDA Nod for Obesity Drug That Rivals Wegovy, OzempicEli Lilly & Co.’s diabetes drug tirzepatide gained US approval for treating patients with obesity under a new name, Zepbound, unlocking blockbuster sales potential in a market that’s expected to hit $100 billion by 2030.
Source: BNNBloomberg - 🏆 83. / 50 Read more »

Richardson Wealth Inc. loses senior advisers to rival wealth managersThe departures by senior advisers have seen the company lose more than 1.4-billion in client assets
Source: globeandmail - 🏆 5. / 92 Read more »